Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Bank Name Merus N.V.
Stock Exchange NASDAQ
Symbol MRUS
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
Chairman
CEO Dr. Ton Logtenberg Ph.D.
Employees 83
Website www.merus.nl
Registered Year 2003

UpdateContent
UpdateContent
UpdateContent